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Background: Tamoxifen (TAM) is widely used in the chemotherapy of breast cancer and as a preventive agent
against recurrence after surgery. However, extended TAM administration for breast cancer induces increased VEGF
levels in patients, promoting new blood vessel formation and thereby limiting its efficacy. Celecoxib (CXB), a
selective COX-2 inhibitor, suppresses VEGF gene expression by targeting the VEGF promoter responsible for its
inhibitory effect. For this study, we had selected CXB as non-steroidal anti-inflammatory drug in combination with
TAM for suppressing VEGF expression and simultaneously reducing doses of both the drugs.
Methods: The effects of CXB combined with TAM were examined in two human breast cancer cell lines in culture,
MCF7 and MDA-MB-231. Assays of proliferation, apoptosis, angiogenesis, metastasis, cell cycle distribution, and
receptor signaling were performed.
Results: Here, we elucidated how the combination of TAM and CXB at nontoxic doses exerts anti-angiogenic
effects by specifically targeting VEGF/VEGFR2 autocrine signaling through ROS generation. At the molecular level,
TAM-CXB suppresses VHL-mediated HIF-1α activation, responsible for expression of COX-2, MMP-2 and VEGF.
Besides low VEGF levels, TAM-CXB also suppresses VEGFR2 expression, confirmed through quantifying secreted
VEGF levels, luciferase and RT-PCR studies. Interestingly, we observed that TAM-CXB was effective in blocking
VEGFR2 promoter induced expression and further 2 fold decrease in VEGF levels was observed in combination than
TAM alone in both cell lines. Secondly, TAM-CXB regulated VEGFR2 inhibits Src expression, responsible for tumor
progression and metastasis. FACS and in vivo enzymatic studies showed significant increase in the reactive oxygen
species upon TAM-CXB treatment.
Conclusions: Taken together, our experimental results indicate that this additive combination shows promising
outcome in anti-metastatic and apoptotic studies. In a line, our preclinical studies evidenced that this additive
combination of TAM and CXB is a potential drug candidate for treatment of breast tumors expressing high levels of
VEGF and VEGFR2. This ingenious combination might be a better tailored clinical regimen than TAM alone for
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Extensive clinical studies over the past 30 years have
shown that tamoxifen (TAM) can reduce the incidence
and regression of breast carcinoma among women
worldwide. A selective estrogen receptor (ER) modulator,
TAM has been used extensively in the clinical manage-
ment of primary and advanced breast cancer and is also
widely employed as a preventive agent after surgery for
breast cancer [1]. High survival rates for patients with
early breast cancer as well as improved quality of life for
patients with metastatic disease are observed in patients
administered TAM. It also reduces the incidence of
breast cancer in patients at risk for developing the dis-
ease and also the recurrence in women with ductal car-
cinoma in situ [2]. The constitutive therapeutic efficacy
of TAM is due to its anti-proliferative action of binding
competitively to ER, thereby blocking the mitogenic ef-
fect of estradiol [3].
Angiogenesis, a major attribute of tumorigenesis, pro-
vides a tumor with oxygen and nutrients [4,5]. Several
different growth factors and cytokines drive angiogenesis
such as VEGF, a predominant pro-angiogenic factor in
human cancer [6,7]. Conventionally, stimulated VEGF
bind to VEGF receptor 2 (VEGFR2) in tumors, contrib-
uting to the proliferation, migration and invasion of
breast cancer cells. On ligand interaction, VEGFR2 is ac-
tivated through receptor dimerization and autophospho-
rylation of tyrosine residues (Y951, Y1175, and Y1214)
in its cytoplasmic kinase domain. VEGF expression may
be conducive to the aggressive phenotype seen in HER2-
positive breast cancer. However, VEGF is also expressed
in a considerable number of HER2-negative tumors,
suggesting that its expression is regulated by additional
processes in breast cancer. VEGF and VEGFR2 are co-
expressed in several epithelial tumors, including breast
cancer, which provides further evidence for an autocrine
pathway for this ligand and its receptor [8]. A relatively
high cytosolic level of VEGF in breast cancer cells has
been associated with the clinical aggressiveness and re-
lapse of the cancer [9]. However, TAM is also known to
increase the expression of vascular endothelial growth
factor (VEGF), which is an undesirable effect in breast
cancer treatment [10,11]. TAM can exert estrogen-like
agonistic effects, such as induction of VEGF mRNA ex-
pression in MCF7 breast cancer cells [12-14]. Specific-
ally, VEGF is one of the gene induced by both TAM and
estrogen in rat uterine cells [15]. An elevated cytosolic
level of the ligand VEGF has been associated with infer-
ior outcome in non-randomized trials of TAM-treated
hormone-responsive patients, indicating that VEGF can
be a marker of response for endocrine therapy [16].
VEGF is a predictor of TAM response among ER-
positive patients with either a low or high fraction of
ER-positive cells [14]. VEGFR2 is an additional predictorof TAM response, with a more notable effect in ER-
positive tumors. The expression levels of VEGFR2 and
VEGF affect the efficacy of TAM in breast cancer pa-
tients [8]. Furthermore, adjuvant TAM administration
results in shorter survival of breast cancer patients who
have higher expression levels of VEGF or VEGFR2 [16].
From the above reports, we interpret that reduction in
TAM dose can decrease the VEGF production. This re-
duction in TAM dose can be achieved by employing
combination therapy.
The combination of TAM and an anti-VEGF signaling
agent inhibits both ER-mediated signaling and VEGF-
stimulated stromal activation, thereby reducing angiogen-
esis [8,17]. Studies have so far indicated that, in human
breast cancers, COX-2 overexpression is correlated with
induction of VEGF expression and therefore tumor angio-
genesis [18]. Inhibition of COX-2 by non-steroidal anti-
inflammatory drugs leads to restricted angiogenesis and
down-regulates production of VEGF [19]. In pancreatic
cancer, celecoxib (CXB), a selective COX-2 inhibitor, sup-
presses VEGF gene expression by targeting the VEGF pro-
moter responsible for its inhibitory effect [20]. In this
context, for this study we had selected CXB as non-
steroidal anti-inflammatory drug in combination with
TAM for suppressing VEGF expression and simultan-
eously reducing doses of both the drugs.
The objective of the current study was to evaluate the
potency of CXB in combination with TAM in inhibiting
breast cancer cell growth, proliferation, and angiogenesis
and reveal the underlying molecular mechanisms in-
volved in TAM-induced apoptosis. We also determined
whether CXB, as an adjuvant agent, could reduce the
dosage of TAM and its consequences in potentially re-
ducing VEGF- and VEGFR2-mediated insensitivity in
breast cancer cells to TAM.
Methods
Cell Lines
Human breast cancer cell lines MCF7, MDA-MB-231,
MDA-MB-468, T-47D, and normal cell lines NIH/3T3
and HaCaT were obtained from the National Centre for
Cell Science (Pune, India) and cultured. Cells were incu-
bated at 37°C in a 5% CO2 atmosphere and at 95%
humidity.
Reagents
Stock solutions of 10 mM TAM and 1 mM CXB (Sigma
Aldrich, St. Louis, MO, USA) were dissolved in dimethyl
sulfoxide (Sigma Aldrich, St. Louis, MO, USA), stored
at −20°C, and diluted in fresh medium just before use.
For western blot analysis, the following antibodies were
used: rabbit monoclonal anti-Bak, anti-CBP, anti-p-MAPK
(Thr202/Tyr204), anti-MAPK, anti-p-Akt (Ser473), anti-
Akt, anti-p-STAT3 (Tyr705), anti-STAT3, anti-p-Src
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VEGFR2, anti-p-BAD (Ser136), anti-BAD, anti-COX-2,
anti-HIFα, anti-MMP-2, anti-VHL, and anti-PARP (all
Cell Signalling Technology, Beverly, MA, USA), mouse
monoclonal anti-β-Actin (Sigma Aldrich, St. Louis, MO,
USA), and mouse monoclonal anti-Bcl2, mouse mono-
clonal anti-Bax, and horseradish peroxidase-conjugated
goat anti-rabbit IgG and anti-mouse IgG (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The pGL3-
VEGFR2-780 plasmid (Addgene plasmid 21307) was
kindly provided by Dr. Donald Ingber (Harvard Medical
School, Boston, MA, USA), and the pGL3-Basic plasmid
was purchased from Promega (Madison, WI, USA).
FuGENE HD transfection reagent was purchased from
Roche Applied Science (Mannheim, Germany); Opti-
MEM I reduced serum medium, TRIzol reagent kit and
Coomassie Blue R-250 from Gibco-BRL, Invitrogen
Corporation, Carlsbad, CA, USA; Nonidet P-40 lysis buf-
fer, chemiluminescent peroxidase substrate, propidium
iodide (PI), 4′,6-diamidino-2-phenylindole (DAPI), 3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide
(MTT), and sense and antisense VEGFR2 oligo primers
from Sigma Aldrich, St. Louis, MO, USA; and pyrogallol
and H2O2 from Merck (Whitehouse Station, NJ, USA).
Stock solutions of PI, DAPI, and MTT were prepared by
dissolving 1 mg of each compound in 1 ml of phosphate-
buffered saline (PBS). The solution was protected from
light, stored at 4°C, and used within 1 month. Stock con-
centrations of 10 mg/ml RNaseA (Sigma Aldrich, St.
Louis, MO, USA) were prepared and kept at −20°C.
Cell viability assay
MCF7 and MDA-MB-231 cells grown in monolayers
were harvested and dispensed in 96 well culture plates
in 100 μl of Dulbecco’s Modified Eagle’s Medium
(DMEM) at a concentration of 5 × 103 cells per well. After
24 h, differential drug concentrations of TAM (0–40 μM),
CXB (0–250 μM), or both (0–5 μM TAM plus 30 μM
CXB) were added to the cells. Cell viability was measured
after 48 h of incubation using the MTT colorimetric assay
at 540 nm with slight modifications to the protocol [21].
The dose-effect curves were analyzed using Prism soft-
ware (GraphPad Prism, CA, USA).
Cell cycle analysis
To determine the cell cycle distribution, 5 × 105 MCF7 or
MDA-MB-231 cells were plated in 60-mm dishes and
treated with their respective half maximal inhibitory con-
centration (IC50) values of TAM, CXB, or both for 48 h.
After treatment, the cells were collected by trypsinization,
fixed in 70% ethanol, and kept at −20°C overnight for fix-
ation. Cells were washed in PBS, resuspended in 1 mL of
PBS containing 100 μg/mL RNase and 40 μg/mL PI incu-
bated in the dark for 30 min at room temperature [22-24].The distribution of cells in the cell-cycle phases were ana-
lyzed from the DNA histogram using a FACS Caliber flow
cytometer (Becton-Dickinson, San Jose, CA, USA) and
CellQuest software (CA, USA).
Wound-closure assay
To assess the effect of TAM and CXB on cell migration,
MCF7 and MDA-MB-231 cells (1 × 105) were plated in
12-well plates in complete growth medium [23,25]. After
24 h of growth, a scratch was made through the conflu-
ent cell monolayer using a 200-μl pipette tip, and the
cells were treated with the IC50 values of TAM, CXB, or
both in 3 ml of complete medium. At 48 h post-
treatment, cells were stained with hematoxylin and
eosin. Cells invading the wound line were observed
under an inverted phase-contrast microscope using 20×,
Leica DMR, Germany. The distance between the two
sides of the scratch was measured after the indicated
time intervals using Leica QWin software, IL, USA. Each
experiment was performed three times with triplicate
samples.
Boyden chamber assay
To test the anti-invasive effect of TAM and CXB, 8-μm
filters were coated with Matrigel (20 μg per filter) and
placed in Boyden chambers. MDA-MB-231 cells (1 ×
105) suspended in DMEM containing 0.1% bovine serum
albumin and treated with IC50 of TAM, CXB, or both,
were added to the top chamber. Conditioned medium
from mouse fibroblast NIH/3T3 cells was used as a
source of chemoattractant and placed in the bottom
compartment of the chamber [26]. After 24 h incubation
at 37°C in a 5% CO2 atmosphere, cells that migrated to
the lower surface of filters were detected with traditional
staining with hematoxylin and eosin. Cells were counted
in five fields of each well under inverted phase-contrast
microscope using 20×, Leica DMR, Germany.
Gelatin zymography
Supernatants from MCF7 and MDA-MB-231 cells (5 ×
104 cells per well, six wells per plate) treated with TAM,
CXB, or both for 48 h were collected for matrix
metalloproteinase (MMP) activity analysis by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis under
non-reducing conditions. A total of 1.2 mg/ml gelatin
was prepolymerized on a 10% polyacrylamide gel as a
substrate. Electrophoresis was carried out at 4°C. The
gel was washed with renaturation buffer (50 mM Tris–
HCl, pH 7.5, 100 mM NaCl, and 2.5% Triton X-100),
which was followed by incubation with a developing buf-
fer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 10 mM
CaCl2, 0.02% NaN3, and 1 μM ZnCl2) at 37°C for 16 h
and staining with Coomassie Blue R-250, as described
previously [27]. The stained bands are observed through
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stained bands was performed by ImageMaster 2D Plat-
inum 7.0 Software (GE Healthcare Life Sciences, NJ,
USA).
Chorioallantoic Membrane (CAM) assay
To determine the in vivo anti-angiogenic activity of
TAM and CXB, a CAM assay was performed as de-
scribed previously with some modifications [28]. Two
day-old fertilized eggs were incubated at 37°C in 60–70%
relative humidity. After 5 d of incubation, a 1- to 2-cm2
window was opened and a sterile round filter paper (5-
mm in diameter; Whatman qualitative filter papers,
Sigma-Aldrich, St. Louis, MO, USA) containing serum-
free medium alone or supplemented with VEGF, TAM,
CXB, or both TAM and CXB (at IC50 concentrations)
was applied onto the CAM of each embryo. After 2 d of
incubation, the upper eggshell was removed, and capil-
laries within 2.5 mm around the filter paper were ob-
served and photographed under a stereomicroscope
(Olympus, SZX16, USA). Neovascularization around the
disk was quantitated by determining the number of an-
giogenic vessels within the CAM around the disk.
Capillary-like tube formation (HUVEC) assay
For the capillary-like tube formation assay, growth
factor-depleted Matrigel from BD Pharmingen, San Jose,
CA, USA was applied to a 96-well tissue culture plate
(50 μl per well). After polymerization of the Matrigel at
37°C for 1 h, human umbilical vein endothelial cells
(HUVECs) (Gibco-BRL, Invitrogen Corporation, Carlsbad,
CA, USA) starved of serum for 2 h were harvested by
using trypsin/EDTA, washed with assay medium, and
seeded at a density of 7.5 × 103 cells per well (final volume
500 μl) on the polymerized Matrigel in the presence or
absence of 30 ng/ml VEGF along with TAM, CXB, or both
[29,30]. Plate was incubated at 37°C, 5% CO2 for 24 h,
then the medium was aspirated and cells were fixed in
10% neutral buffered formalin. Tube formation was
observed for 24 h, representative pictures were taken at
10× magnifications under a stereomicroscope (Olympus,
SZX16, USA) and tubes were counted in five random
fields.
Western blotting analysis
For phosphoprotein studies, MCF7 and MDA-MB-231
cells (1 × 106 cells per 100 mm plate) were treated with
TAM, CXB, or both at their respective IC50 doses for 24 h.
Cells in control wells were treated with 0.1% dimethyl sulf-
oxide for 1 h. All cells were activated with recombinant hu-
man epidermal growth factor (25 ng/mL) for 30 min. The
cells were then scraped and lysed in Nonidet P-40 lysis buf-
fer. Cell extracts (50 μg of protein) were separated on a so-
dium dodecyl sulfate-polyacrylamide electrophoretic geland transferred to nitrocellulose membranes, which
were blocked in 3% bovine serum albumin for 2 h. After
blocking, the membranes were incubated with primary
antibodies overnight at 4°C and then with horseradish
peroxidase-conjugated secondary antibody for 2 h at
room temperature [24]. Proteins were visualized by
exposing the chemiluminescence substrate (Sigma) to
X-OMAT AR autoradiography film (Eastman Kodak,
Rochester, NY, USA).
Transfection studies
MCF7 and MDA-MB-231 cells were plated in 60-mm
petri dishes at a density of more than 4 × 105 per plate
in DMEM supplemented with 10% fetal bovine serum.
After being allowed to grow for 16–20 h, cells were
starved for 6 h with 2% fetal bovine serum. Confluent
cells (70–80%) were transiently transfected with 5 μg of
pGL3-VEGFR2-780 plasmid with 7.5 μl of FuGENE HD
transfection reagent in 100 μl of Opti-MEM I reduced
serum medium according to the manufacturer’s protocol
(Roche Diagnostics, Mannheim, Germany) [31]. After
24 h of transfection, the mix was replaced with complete
medium containing TAM, CXB, both, or neither for
24 h and then lysed in luciferase lysis buffer (Sigma)
[32,33]. Luciferase activity was measured with a
luminometer (Varian cary eclipse, Palo Alto, CA, USA)
and a luciferase assay kit (Sigma) and was normalized to
β-galactosidase activity. All luciferase experiments were
done in triplicate and repeated three times. Data is
presented as means ± SD.
Measurement of VEGF levels
To measure VEGF levels, MCF7 and MDA-MB-231 cells
(5 × 105 cells per well, six wells per plate) were plated
and incubated under culture conditions overnight, and
the medium was replaced by serum-free culture condi-
tioned medium. TAM, CXB, or both were added to the
culture, and the medium was collected at 72 h [10].
VEGF levels were measured using a VEGF enzyme-
linked immunosorbent assay (ELISA) kit (DVE00, R&D
Systems, Minneapolis, MN, USA) according to the man-
ufacturer’s instructions. The optical density at 570 nm of
each well was measured using an automated microplate
reader (model 550, Bio-Rad, Hercules, CA, USA).
Reverse transcription-polymerase chain reaction (RT-PCR)
By using the TRIzol reagent kit, total RNA was extracted
from MCF7 and MDA-MB-231 cells treated with TAM,
CXB, or both. RT-PCR was run using a one-step RT-
PCR kit (Gibco-BRL, Invitrogen Corporation, Carlsbad,
CA, USA). β-Actin was used as an internal control. The
sense and antisense primers for the VEGFR2 gene were
5′-TGACCAACATGGAGTCGTG-3′ and 5′-CCAGAG
ATTCCATGCCACTT-3′, respectively. The sense and
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AGACCTTCAA-3′ and 5′-TCTTTGCGGATGTCCAC
G-3′, respectively. PCR was performed in a 25-μL reac-
tion volume. The cycling conditions were 94°C for 5 min;
35 cycles of 94°C for 30 s, 54°C for 45 s, and 72°C for 60 s;
and a final extension at 72°C for 10 min. Amplified prod-
ucts were separated by 1.2% ethidium bromide-stained
agarose gel electrophoresis and viewed under ultraviolet
light. Electrophoresis photos were transferred to a com-
puter and analyzed using the Gel Doc image system (Bio-
Rad) [34]. Semiquantitative analysis was performed by
comparing the results of VEGFR2 mRNA with β-Actin.
Animal studies
Tumor response to CXB and TAM was studied using S180
tumor bearing female Swiss albino mouse model. Our
study was approved by the Department of Biotechnology
(DBT), INDIA under the project number: E-1/MMSMST/
12, at Indian Institute of Technology Kharagpur, INDIA
and the mice were maintained in accordance with the
institute animal ethical committee (IAEC) guidelines ap-
proved by Indian Council of Medical Research (ICMR),
New Delhi. The mice were housed and acclimatized in a
pathogen-free environment at our institute’s animal facility
for 1 week prior to injection with mouse S180 sarcoma
cells. Exponentially growing S180 cells were harvested and
a tumorigenic dose of 2.5 × 106 cells was injected intraperi-
toneally into 6- to 7-week-old female Swiss albino mouse
[24,35,36]. Tumors were allowed to grow in the mouse for
7 d, when the animals were randomly assigned into one of
four treatment groups (5 mice per group). The control
group received 1% polysorbate resuspended in deionized
water. The other three groups were treated with CXB
(3.7 mg/kg body weight), TAM (2 mg/kg body weight), or
CXB plus TAM (2 and 1 mg/kg body weight, respectively)
intraperitoneally on alternative days for 2 weeks. The doses
were selected based on previous experiments [37,38].
Mouse body weight was measured before the treatment
injections were given and on the 7th and 14th day of
treatment. On 15th day, the animals were euthanized
using chloroform and their liver and kidney tissues were
collected for enzymatic assays. Spleens were collected
and cultured for a splenocyte surveillance study. Fur-
thermore, S180 cells were collected from the site of
treatment injections for in vivo and ex vivo cell cycle
phase distribution studies.
Assay of splenocyte proliferation
Spleens from treated mice were collected, and single-cell
spleen suspensions were pooled in serum-free DMEM
by filtering the suspension through a sieve mesh with
the aid of a glass homogenizer to exert gentle pressure on
the spleen fragments. Samples were washed twice in PBS
0.1% (w/v) bovine serum albumin. After centrifugation at200 g for 5 min, the cells were placed into 96-well flat-
bottomed microplates in triplicate at 2.5 × 103 cells per
well in DMEM supplemented with 10% fetal bovine
serum. The cells were then incubated in a total volume of
100 μL per well. Serum-free DMEM was used as control
[39]. After 24 h, cell proliferation was measured using the
MTTassay.
Measurement of antioxidative enzyme activity
Parts of mouse liver and kidney tissues were homoge-
nized in 0.1 M Tris buffer (pH 7.0), and the homogenate
was centrifuged at 4000 g for 20 min. The supernatant
was immediately assayed for catalase (CAT) and super-
oxide dismutase (SOD). Determination of CAT activity
was performed at room temperature in a 1-ml mixture
containing clear cell lysate, 100 mM phosphate buffer
(pH 7.0), and 10 mM of H2O2 [40]. The decomposition
of H2O2 is followed directly by a decrease in absorbance
at 240 nm spectrophotometrically using Perkin Elmer
Lambda45. CAT activity was expressed in micromoles of
H2O2 consumed per minute per milligram of protein.
Total SOD was determined using the pyrogallol assay,
based on the competition between pyrogallol oxidation
by superoxide radicals and superoxide dismutation by
SOD [41], and spectrophotometrically read at 420 nm
using Perkin Elmer Lambda45. SOD activity was
expressed in units per minute per milligram of protein.
Measurement of ROS
To measure intracellular reactive oxygen species (ROS),
10 μM 2′,7′-dichlorofluorescein diacetate (DCFDA) was
used [28]. MCF7 and MDA-MB-231 (5 × 104 cells per
well, six wells per plate) were treated with IC50 of TAM,
CXB, or both for 24 h; washed with PBS; stained with
DCFDA at a final concentration of 1 μg/ml for 30 min
at 37°C; and subjected to flow cytometry (FACS Calibur
flow cytometer, Becton-Dickinson). Data were acquired
and analyzed with CellQuest software.
Statistical analysis
All the statistical analysis was performed by Graphpad
Prism 5 software. Data are presented using mean ± S.D.
The statistical significance was determined by using
one-way analysis of variance (ANOVA). ***P < 0.001
and **P < 0.05 were considered significant.
Results
CXB enhances TAM-induced breast cancer cell death
To determine the effect of TAM, CXB, and both on the
cell viability of breast cancer cells in vitro, ER-α-positive
MCF7 and T-47D cells and ER-α-negative MDA-MB-231
and MDA-MB-468 cells were treated with increasing
concentrations of CXB (0–250 μM) or TAM (0–40 μM).
Treatment with TAM alone resulted in similar IC50
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MB-468 cell lines (9.06 ± 0.29, 8.99 ± 0.55, 13.05 ± 0.91,
and 11.56 ± 0.65 μM, respectively) (Figure 1A). Treat-
ment with CXB alone also resulted in IC50 values that
were similar in these four cell lines (113.3 ± 0.760, 109.3 ±
0.782, 109.8 ± 0.963, and 121.7 ± 0.240, respectively)
(Figure 1B). Combination treatment (0–5 μM TAM in
the presence of 30 μM CXB) resulted in a leftward shift
of the concentration-response curve such that the IC50
values were reduced to 2.76 ± 0.10, 1.82 ± 0.13, 2.05 ± 0.13,
and 2.86 ± 0.12 μM, respectively (Figure 1C), indicating
that treatment with both agents was more cytotoxic than
either one alone. The treatment regimens resulted in little
toxicity in NIH/3T3 and HaCaT cell lines, demonstrating
that TAM and CXB are non toxic to normal cell lines.
Based on the results we have chosen respective IC50’s of
drugs for further treatments throughout the study.
CXB enhances TAM-induced apoptosis and growth
inhibition
The effects of TAM and CXB on the cell cycles of
MCF7 and MDA-MB-231 cells were then analyzed.Figure 1 TAM combined with CXB additively inhibits survival of breas
T-47D, MDA-MB-468, NIH/3T3 and HaCaT cells treated with (A) TAM, (B) CX
means ± SE of three independent experiments p < 0.05. (D) Representative
cells and their cell-cycle distribution after 48 h of treatment, as determined
plus CXB; UT, untreated.MCF7 cells (IC50 values: 114 μM CXB, 9 μM TAM)
treated with TAM or CXB had an increased percentage
of apoptotic cells (i.e., cells in the sub-G1 phase) com-
pared with untreated cells (Figure 1D, top row). Simi-
larly, MDA-MB-231 cells (IC50 values: 110 μM CXB,
13 μM TAM) had an increased percentage of apoptotic
cells compared with untreated cells (Figure 1D, bottom
row). The low-dose combination (30 μM CXB plus
2 μM TAM) resulted in an even greater percentage of
apoptotic cells than the higher doses of either drug alone
did. These data are consistent with the results from the
MTT assay. Taken together, these results indicate an
additive mechanism of TAM and CXB in inducing cell
death through apoptosis.
Effect of TAM and CXB on migration and invasion of
breast cancer cells
To ascertain the inhibitory effect of TAM and CXB on
breast cancer metastasis, we used the wound-healing
assay to investigate their effects on the migration poten-
tial of MCF7 and MDA-MB-231 cells. A wound through
a confluent cell monolayer was created with a pipettet cancer cells. In vitro cell viability assay of MCF7, MDA-MB-231,
B, or (C) both (0–5 μM TAM plus 30 μM CXB) for 48 h. Data are
histogram of MCF7 cells (top row) and MDA-MB-231 (bottom row)
by flow cytometry followed by staining of cells with PI. T + C, TAM
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recorded by microscopic observation. After 48 h, the
wound had almost completely filled in the cleared region
in untreated MCF7 and MDA-MB-231 cells (Figures 2A
and 2B). The migration of MDA-MB-231 cells was re-
duced with TAM or CXB with respect to the untreated
cells and greatly reduced when both TAM and CXB
were used. However, TAM and CXB had limited effects
in MCF7 cells, which might be explained by the poor in-
vasiveness of this cell line.
The ability of TAM and CXB to reduce the invasive-
ness of MDA-MB-231 cells was further investigated by
the Boyden chamber assay. Cells treated with IC50 con-
centrations of TAM, CXB, or both for 24 h were plated
in the upper chamber, and the number of cells that
moved to the underside of the coated membrane was
counted 12 h later using a light microscope. The cham-
bers were stained with hematoxylin and eosin and ana-
lyzed by photography. Again, compared with the results
with either agent alone, the combination of TAM and
CXB greatly inhibited MDA-MB-231 cell invasion
(Figure 2C).Figure 2 Anti-invasive and anti-migratory potential of TAM and CXB
eosin-stained cell images migrating into the wounded area in an in vitro w
(B) Quantification of wound-healing results. Data are means ± SE of three r
photomicrographs of Boyden chamber assays of MDA-MB-231 cell invasion
(D) Top: Gelatinolytic activity of MMP-2 in MCF-7 cells and MDA-MB-231 ce
levels in gelatin blot. Data are means ± SE of three independent experimenTAM and CXB inhibit activation of MMP-2 in breast cancer
cell lines
Substantial levels of MMP secretion have been reported
for metastatic breast cancer tumors and to be associated
with the degradation of extraceullular matrix, a crucial
step in metastasis [42]. Zymographic analyses showed
that TAM and CXB additively inhibited MMP-2 activity
in both MCF7 and MDA-MB-231 cells (Figure 2D).
Thus, apart from its anti-VEGF effect in inhibiting
tumor cells, this combination treatment can inhibit the
metastasis and spread of breast cancer cells by reducing
MMP-2. The addition of CXB enhanced the anti-
metastatic potential by more than 2-fold in comparison to
control. However, the impact of TAM and CXB on MMP-
9 activity is inconclusive because an extremely low level of
MMP-9 was detected in untreated cells (data not shown).
TAM and CXB inhibit in vivo angiogenesis and in vitro
tube-like capillary formation
The CAM model was used to investigate the effect of TAM
and CXB on angiogenesis in vivo [43]. CAM assay with the
PBS group did not show any notable avascular zone aroundin MCF7 and MDA-MB-231 cells. (A) Representative hematoxylin- and
ound healing assay at times 0 h and 48 h. Scale bars, 100 μm.
andom widths along the wound. P < 0.05. (C) Representative
through Matrigel. Cells were stained with hematoxylin- and eosin.
lls treated for 48 h. Bottom: Densitometric analysis of MMP-2 protein
ts. P < 0.05 (t-test).T + C, TAM plus CXB; UT, untreated cells.
Kumar et al. BMC Cancer 2013, 13:273 Page 8 of 15
http://www.biomedcentral.com/1471-2407/13/273the implanted filter paper (Figures 3A and 3C). In contrast,
treatment with TAM, CXB, and both agents together
inhibited the development of new embryonic capillaries
and produced an avascular zone around the implanted filter
papers. The inhibition of angiogenesis was most prominent
when TAM and CXB were combined.
Next we performed tube formation assays with
HUVECs, which are widely used as in vitro assays for
angiogenesis. After 24 h, HUVECs treated with PBS only
rapidly aligned and formed hollow, tube-like structures,
whereas HUVECs treated with both TAM and CXBFigure 3 Anti-angiogenic and anti-tube formation potential of TAM a
loaded with serum-free medium alone or supplemented with vascular end
(B) Inhibition of capillary-like tube formation in vitro (HUVECs assay). HUVEC
coated with 50 μl Matrigel. Then, TAM and/or CXB were added. Cells were
Tube formation was observed for 24 h and images were taken (magnificati
means ± SD of blood vessel count for four independent experiments P < 0.
formation assay was counted using light microscopy. Data are presented a
analysis of apoptotic and angiogenic markers in MCF7 and MDA-MB-231 ce
control for equal loading. Representative blots from three independent expshowed a significant reduction of tube formation com-
pared with TAM or CXB alone (Figures 3B and 3D). Col-
lectively, these results suggest that CXB enhances the
anti-angiogenic action of TAM by inhibiting HUVEC dif-
ferentiation into tube-like structures during angiogenesis.
TAM and CXB inhibit angiogenesis via von Hippel-Lindau
tumor suppressor protein (VHL)-mediated degradation of
hypoxia-inducible factor 1α (HIF-1α)
VHL regulates activated HIF-1α through ubiqitination
by prolyl hydroxylation under normoxia conditions [44].nd CXB. (A) In vivo CAM assay. CAMs were implanted with sponges
othelial growth factor (VEGF), TAM, CXB, or TAM plus CXB.
s were seeded (7.5 x 103 cells/well) into a 96-well tissue culture plate
incubated in HUVEC growth medium in a 37°C, 5% CO2 incubator.
on of 10×). (C) Number of blood vessels in CAM assay was counted as
05. (D) Number of capillary-like structures in capillary-like tube
s means ± SD of four independent experiments. (E) Western blotting
lls treated with TAM, CXB, or both. β-Actin was used as an invariant
eriments are shown. T + C, TAM plus CXB; UT, untreated cells.
Figure 4 (See legend on next page.)
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Figure 4 TAM- and CXB- inhibit overexpressed VEGFR2 induced angiogenesis in MCF7 cells (left) and MDA-MB-231 cells (right).
(A) Cells were treated with TAM, CXB, or both and incubated in serum-free conditioned medium for 24 h. VEGF levels were determined by ELISA.
(B) Cells (5 × 105/ml) were transfected with VEGFR-luciferase plasmid, incubated for 24 h, and treated with TAM, CXB, or both for 4 h. Whole-cell
extracts were then prepared and analyzed for luciferase activity. Absolute values are normalized to untreated cells without VEGFR2. Data are
means ± SD of three independent experiments. (C) Western blot analysis for VEGFR2 and phosphorylated VEGFR2. (D) Densitometric analysis of
phosphorylated VEGFR2 protein levels. Data are means ± SD of three independent experiments. P < 0.05 (t-test). (E) The level of VEGFR2 mRNA in
MCF7 and MDA-MB-231 cells examined by RT-PCR analysis following TAM, CXB and T + C treatment for 24 h. Data are means ± SD of three
independent experiments using different cell preparations. *P < 0.05 vs. untreated cells. EGF, epidermal growth factor; T + C, TAM plus CXB; UT,
untreated cells.
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http://www.biomedcentral.com/1471-2407/13/273In reduced oxygen conditions, HIF-1α binds to hypoxia-
responsive elements which, in turn, stimulate the tran-
scriptional coactivators CREB-binding protein and induces
transcription of various target genes involved in tumor in-
vasion, cell survival, and angiogenesis. Apart from its role
in angiogenesis, HIF-1α promotes invasion by regulating
the expression of COX-2, MMP-2, and other cytokines
and growth factors [45]. Our western blotting results dem-
onstrated that the combination of TAM and CXB modu-
lated VHL expression in MCF7 and MDA-MB-231 cells,
thus regulating HIF-1α, which in turn binds to CREB-
binding protein, thereby altering the expression of the
downstream effector molecules involved in metastasis and
angiogenesis (e.g., MMP-2, COX-2 and VEGF) (Figure 3E).
These features have rendered HIF-1α as an attractive tar-
get for our study in inhibiting angiogenesis.
TAM plus CXB lowers VEGF production in breast cancer
cells
We investigated the role of TAM and CXB in the inhib-
ition of secretory VEGF, a pro-angiogenic factor respon-
sible for the migration and invasion of breast cancer
cells. VEGF secretion in serum-free culture conditioned
medium was assessed in MCF7 and MDA-MB-231 cells
by ELISA 24 h post-treatment. In both cell lines, TAM
alone considerably upregulated VEGF secretion and the
combination of CXB and TAM notably decreased VEGF
secretion compared with no treatment (Figure 4A). Pre-
cisely, in control cells VEGF levels were found to be
approximately 600 and 280 pg/mL in MCF7 and MDA-
MB-231 cells, respectively whereas CXB treatment alone
does not showed any significant change in the secreted
VEGF levels in both cell lines. However, induced VEGF
was suppressed in combination treatment to 400 pg/mL
in MCF7 and 190 pg/mL in MDA-MB-231 in compari-
son to TAM alone treated MCF7 (1000 pg/mL) and
MDA-MB-231 (320 pg/mL).
TAM plus CXB inhibits VEGF-mediated stimulation of
VEGFR2 promoter activity
To further confirm the role of enhanced activity induced
by treatment with TAM and CXB in the transcriptional
regulation of the VEGFR2 gene, cells were transiently
transfected with a chimeric luciferase gene fused with the5′ region of the VEGFR2 promoter (Tischer et al., 1991),
and the activity of the promoter was assayed in the pres-
ence and absence of VEGFR2 gene after treatment with
the IC50 doses for 24 h. Transfection induced VEGFR2
promoter activity in both MCF7 and MDA-MB-231 cells.
To determine the relative fold change in VEGFR2 pro-
moter activity, we normalized with respect to untrans-
fected control (null) cells. VEGFR2 transfected untreated
cell (UT) showed an approximately 3- and 2-fold increase
in promoter activity as compare to null in MCF7 and
MDA-MB-231 cells, respectively. There was an approxi-
mately 1.2-fold increase in VEGFR2 promoter activity
in TAM-treated and approximately 1.5-fold increase in
CXB-treated whereas fold increase was observed <1 in
TAM-CXB treated with respect to null in both cell
lines. Concisely, TAM and CXB was effective in blocking
VEGFR2 promoter induced expression in MCF7 and
MDA-MB-231 cells (Figure 4B). Taken together, the
results of this experiment demonstrated that the activity
of the VEGFR2 promoter is downregulated by CXB
under the influence of TAM in both the cell lines.
Besides, it also interferes with the phosphorylation of
VEGFR2 (Figures 4C and 4D). Further, RT-PCR analysis
was also in accordance with the VEGFR2 promoter
luciferase activity (Figure 4E).
TAM and CXB in combination suppress VEGFR2-mediated
Src/STAT3/Akt/MAPK signaling
VEGFR2 is the major receptor of VEGF in angiogenesis,
and the VEGF/VEGFR2 pathway plays a central role in
angiogenesis. TAM and CXB together strongly inhibited
VEGF-activated VEGFR2 phosphorylation at Tyr1175 in
western blotting analysis of MCF7 and MDA-MB-231
cells (Figures 4C and 4D). To determine whether this
combination treatment could inhibit downstream signal-
ing of VEGFR2, we screened some key factors involved in
the VEGFR2 signaling pathway. Here, EGF was employed
as a growth stimulant to induce phosphorylation levels of
regulatory proteins. For both cell lines, the phosphoryl-
ation activities of Src and STAT3 were much lower with
the combination than with either drug alone (Figures 4C,
4D and Figure 5). Because STAT3 plays an important role
as a critical transcription activator in angiogenesis, we
then analyzed the expression of STAT3 downstream
Kumar et al. BMC Cancer 2013, 13:273 Page 11 of 15
http://www.biomedcentral.com/1471-2407/13/273genes. Results showed that compared with TAM or CXB
alone, TAM-CXB together inhibited the expression of
anti-apoptotic Bcl-2 protein and increased the levels of
pro-apoptotic Bax and Bak proteins (Figure 3E). STAT3 is
also involved in the inhibition of apoptosis in endothelial
cells. We found that various death substrates, such as poly
(ADP-ribose) polymerase (PARP) (Figure 3E) and other
molecules at conserved aspartic acid residues (data not
shown), were more strongly activated by TAM-CXB in
combination than by either drug alone in MCF7 and
MDA-MB-231 cells. Taken together, these western blot-
ting analysis results suggest that the combination of
TAM-CXB blocks the VEGF-induced Src/STAT3 signal-
ing pathway. Further, our western blotting analysis proved
the involvement of VEGFR2 signaling in the inhibition of
AKT and MAPK and the phosphorylation of the down-
stream protein Bad (Figure 5). Bad plays important roles
in tumor cell function, angiogenesis, and tumor growth.TAM plus CXB causes significant inhibition of S180
tumors
We assessed the in vivo therapeutic efficacy of TAM and
CXB in Swiss albino mice bearing S180 tumors. TAM
and CXB each induced tumor regression and slowed
tumor growth in these mice treatment groups (Figure 6A).
Body weight of the animals was measured during the 7th
and 14th day of treatment. Untreated mice and mice
treated with TAM or with CXB gained weight over time;Figure 5 Phosphoprotein and total protein expression profiles of MC
TAM and/or CXB. Phosphorylated levels of p-Src (Tyr416), p-STAT3 (Tyr705
determined by western blot analysis using their specific antibodies. β-Actinin contrast, whereas mice treated with both TAM and
CXB maintained their weight (Figure 6B).CXB increases TAM-induced Splenocyte proliferation
To assess the efficacy of TAM and CXB in modulating
splenocyte proliferation, spleen cells of treated S180 mice
were isolated and cultured in DMEM supplemented with
10% fetal bovine serum for 24 h and subjected to in vitro
proliferation assays. Compared with untreated mice, mice
treated with TAM, CXB, or both displayed approximately
1.5-, 1.2-, and 2.0-fold increases, respectively, in splenocyte
proliferation (Figure 6C).Apoptotic effects of TAM and CXB on S180 tumor cells
To assess the therapeutic efficacy of TAM and CXB,
cells isolated from the intraperitoneally injected region
of sacrificed mice were subjected to cell cycle analysis.
Imprints of cytotoxic effects of these drugs were found
at this region. The proportion of cells from untreated mice
or mice treated with TAM, CXB, or both agents that was
in the sub-G1 phase was 0.07 ± 0.56%, 2.8 ± 0.16%, 1.55 ±
0.84%, and 3.69 ± 0.63%, respectively (Figure 6D). Ex
vivo cell cycle studies showed analogous results (4.61 ±
0.27%, 29.06 ± 0.13%, 17.52 ± 0.77%, and 51.67 ± 0.34%,
respectively), to that of in vitro studies as shown in
(Figure 6E) thereby confirming the additive therapeutic
effect of the drugs.F7 (left) and MDA-MB-231 (right) breast cancer cells treated with
), p-Akt (Ser473), p-MAPK (Thr202/Tyr204) and p-Bad (Ser136) were
was used as an invariant control for equal loading.
Figure 6 Antitumor activity of TAM and CXB in Swiss albino mice bearing S180 tumors. Mice were intraperitoneally injected with TAM
(2 mg/kg body weight), CXB (3.7 mg/kg body weight), or both (2 and 1 mg/kg body weight, respectively) on alternative days after tumor cell
implantation and continued for 2 weeks. (A) Mice images bearing S180 tumors with different treated groups at the time of sacrifice, (B) Animal
body weight on 7th and 14th day of treatment. Data are means ± SD of three independent experiments. (C) MTT assay of proliferation of
splenocytes from mice. Data are means ± SD of three independent experiments. p < 0.05 compared with untreated mice. (D) Cell-cycle phase
distribution study of S180 cancer cells isolated from the intraperitoneal region of treated animals exposed to TAM and CXB for 48 h followed by
PI staining. (E) Cell-cycle phase distribution analysis of ex vivo grown S180 cells exposed to TAM and CXB for 48 h followed by PI staining.
Enzyme activity assays of catalase (F) and superoxide dismutase (G) from liver and kidney tissue homogenates of S180 tumor-bearing Swiss
albino mice after drug treatment. Data are means ± SD of three independent experiments. (H) Intracellular ROS accumulation in MCF-7 cells (top)
and MDA-MB-231 cells (bottom) treated with TAM, CXB, or both for 24 h was assessed by DCFDA staining and performed flow cytometry. T + C,
TAM plus CXB; UT, untreated cells.
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CAT and SOD assays were performed to assess the role
of reactive oxygen species in VEGF induction [46]. The
activities of the antioxidant enzymes CAT and SOD in
the liver and kidney of S180 tumor-bearing mice were
assayed. For both TAM- and CXB-treated mice, the levels
of CAT activity in liver tissue or in kidney tissue were sig-
nificantly lower than those of untreated mice (Figure 6F).
In addition, for mice treated with both TAM and CXB,CAT activity in liver or kidney tissue was significantly
lower than that in mice treated with TAM or CXB
alone. Similar results were observed with SOD activity
(Figure 6G).
Role of ROS in the combined effect of TAM and CXB
To establish whether treatment with TAM and CXB for
24 h induces ROS-dependent apoptosis, we investigated
whether they increase ROS generation in MCF7 and
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of H2O2 using DCFDA staining. Flow cytometric
analysis revealed that for both cell lines, TAM resulted
in higher generation of ROS than CXB (Figure 6H). In
addition, treatment with both agents increased ROS pro-
duction by over 50% as compared with the control cells,
which was associated with enhanced apoptosis.
Discussion
TAM has been described as ‘the most important drug
developed in the history of breast cancer’ [47]. The
introduction of TAM heralded a new approach to the
treatment of breast cancer. Initial clinical studies of
TAM displayed its antiangiogenic and VEGF reducing
ability in various tumor models [5,48-51]. Despite its
meritorious stand in the treatment of breast cancer,
prolonged administration of TAM causes intracellular
VEGF levels to rise in patients, an undesirable response
leading to enhanced metastasis and angiogenesis and
resulting in inferior outcomes [14,52]. In addition, auto-
crine VEGF/VEGFR2 loop activation confers resistance
to TAM in breast cancer cells [8]. In this perspective, we
made an attempt to decrease intracellular VEGF levels
by reducing the TAM dose in ER-positive and ER-
negative breast cancer cells. For accomplishing the above
goal we employed combination therapy by decreasing
TAM dose and choose CXB, a selective COX-2 inhibitor
as an adjuvant agent [53] that induces apoptosis through
inhibiting angiogenesis by suppressing VEGF expression
in gastric and breast cancers [20,54]. From the above re-
port, in the current study we aimed to determine the ex-
pression profile of VEGFR2 and quantify VEGF in both
MCF7 and MDA-MB-231 breast cancer cells treated
with TAM, CXB or both. In our study, we observed re-
duction in VEGF levels in TAM and CXB treated MCF7
but no significant change in MDA-MB-231. Interest-
ingly, we also found that the activity of VEGFR2 was
inhibited by TAM and CXB in very low concentrations
than either drug alone.
STAT proteins comprise a transcription factor family
that participates in normal cellular events, such as prolif-
eration, apoptosis and angiogenesis [55]. An increasing
amount of evidence has suggested that STATs, mainly
STAT3, play a critical role in angiogenesis. Indeed,
activated STAT3 is a mediator and biomarker of VEGF-
induced endothelial activation [56]. The VEGF/VEGFR2-
mediated STAT3 signaling pathway is a potential key
target of anti-angiogenic tumor therapy [57,58]. Here,
we elucidated the VEGFR2-activated STAT3 signaling
pathway in human breast cancer cells. In our study, the
activity of VEGFR2 was more strongly inhibited, and
thus the activation of Src and STAT3 is suppressed by
the combination of CXB and TAM (in very low concen-
trations) than either drug alone. The reduction ofSTAT3 activation, in turn, inhibited the downstream
gene expression of the anti-apoptotic Bcl-2 protein and
increased the expression levels of the pro-apoptotic Bax
and Bak proteins. Furthermore, the core proteins in-
volved in apoptosis, including various death substrates
such as PARP, were activated when treated with CXB
and TAM in combination, which was consistent with
the results of our apoptosis analysis.
VEGFR2 mediates Src regulation of endothelial cell
junctions and vascular permeability [59,60]. Src proteins
appear to be important for multiple aspects of tumor
progression, including proliferation, disruption of cell-
cell contacts, migration and invasiveness [61]. TAM and
CXB additively reduced tumor migration and invasion;
this finding was supported by our wound-healing and
Boyden chamber assay results. We also demonstrated
that CXB and TAM in combination interfered with the
binding of VEGF to VEGFR2, thus suppressing the phos-
phorylation of Src protein and contributing to anti-
metastatic activity leading to decreased MMP expression,
as confirmed through the gelatin zymography and
western blot analyses. Our study also showed that the
ROS level decreased after co-administration of TAM
and CXB confirmed through our FACS and in vivo
studies.
Moreover, we proved the involvement of VEGFR2 sig-
naling in the inhibition of Akt and MAPK molecules
and in the phosphorylation of downstream proteins such
as Bad and Bax, which play important roles in angiogen-
esis and apoptosis [24]. Supporting evidence concerning
in vivo anti-angiogenic effects of TAM-CXB additively
came from our chick embryonic CAM model and
HUVEC-based tube formation assay with an in vitro
model. All these results showed that treatment with both
TAM and CXB suppressed the VEGFR2 pathways.
To thoroughly understand the extent of VEGF/
VEGFR2 inhibition by TAM and CXB in combination,
we performed VEGFR2 overexpression studies through
luciferase assays and quantified the serum VEGF secre-
tion levels. Results showed an approximately 3- and 2-
fold increase in VEGFR2 promoter activity in transfected
MCF7 and MDA-MB-231 cells, respectively. The ob-
served VEGF-mediated up-regulation of VEGFR2 pro-
moter activity in MCF7 and MDA-MB-231 cells was
effectively suppressed by TAM and CXB in combination
at very low concentrations (IC50 values) as compared
with either drug alone. Finally, to validate the extent of
VEGFR2 expression at mRNA levels, we performed RT-
PCR studies and came up with similar results as the
overexpression studies.
Conclusion
In summary, our study indicated that the combination
of TAM and CXB at nontoxic levels exerts potent anti-
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http://www.biomedcentral.com/1471-2407/13/273angiogenic effects by specifically targeting VEGF/VEGFR2
autocrine signaling through ROS generation. This additive
combination suggests an effective approach with promis-
ing results in anti-metastatic and apoptotic studies. In a
line, our preclinical studies suggest that this combination
is a potential candidate treatment against breast tumors
expressing high levels of VEGF and VEGFR2.
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